New Research Suggests Migraine CGRP Inhibitors May Be Linked to Lower Glaucoma Risk

Introduction

A recent large multinational cohort study published in the journal Neurology (American Academy of Neurology) has explored a potential connection between migraine preventive therapy and eye health. The findings suggest that calcitonin gene-related peptide inhibitors, commonly known as CGRP inhibitors, may be associated with a reduced risk of developing glaucoma in adults with migraine.

This topic is gaining attention in both neurology and ophthalmology because migraine and glaucoma may share overlapping neurovascular mechanisms. The study provides early but important real-world evidence that could influence future research on neuroprotective effects of migraine treatments.

What the Study Looked At

The study analyzed data from more than 73,000 adults diagnosed with migraine who were treated with preventive medications between 2018 and 2024. Researchers compared two groups:

• Patients using CGRP inhibitors such as erenumab, fremanezumab, galcanezumab, eptinezumab, atogepant, and rimegepant
• Patients using traditional migraine preventives such as beta-blockers, antidepressants, anticonvulsants, and ACE inhibitors

The main outcome was the development of glaucoma over a follow-up period of up to three years.

To reduce bias, the researchers used a large multinational electronic health record database and applied propensity score matching to ensure both groups were comparable in age, sex, and underlying health conditions.

Key Findings

The results showed a statistically significant reduction in glaucoma risk among patients using CGRP inhibitors:

• 0.42 percent of CGRP inhibitor users developed glaucoma
• 0.61 percent of non-CGRP users developed glaucoma
• Hazard ratio: 0.75 (95 percent confidence interval 0.61 to 0.92)

This means CGRP inhibitor users had about a 25 percent lower relative risk of developing glaucoma compared to those on other migraine preventive therapies.

The protective association was especially seen with monoclonal antibody CGRP inhibitors, while gepants did not show a statistically significant effect.

Why Might Migraine Drugs Affect Glaucoma Risk?

Researchers believe the link may be explained by shared biological pathways involving neurovascular regulation.

CGRP and Eye Health

Calcitonin gene-related peptide plays a role in:

• Regulation of blood vessel tone
• Neurogenic inflammation
• Pain transmission in migraine
• Ocular blood flow and intraocular pressure regulation

Because glaucoma involves damage to the optic nerve often influenced by intraocular pressure and inflammation, CGRP signaling may be indirectly involved in disease development.

Possible Protective Mechanisms

The study and prior research suggest two main mechanisms:

1. Intraocular pressure regulation
   CGRP may increase aqueous humor production. Blocking this pathway could potentially reduce eye pressure, which is a major risk factor for glaucoma.
2. Neuroinflammation reduction
   Chronic inflammation contributes to retinal ganglion cell damage. CGRP inhibition may reduce inflammatory signaling, potentially protecting optic nerve health.

Important Subgroup Results

The protective association was not uniform across all groups:

• Stronger effect in adults aged 45 and older
• More pronounced benefit in women
• Lower risk observed in chronic migraine and migraine without aura
• No clear association in patients with hypertension subgroups
• Significant reduction in ocular hypertension risk, but not clearly in primary open-angle glaucoma

These differences suggest that the effect may depend on underlying risk factors and disease mechanisms.

How the Study Was Conducted

This was a retrospective cohort study using the TriNetX global health research network, which includes electronic medical records from more than 220 healthcare institutions worldwide.

Key methodological features included:

• Propensity score matching to reduce confounding
• Active comparator design
• Up to 3 years of follow-up
• Cox proportional hazards modeling
• Multiple sensitivity and subgroup analyses

The study was classified as Class II evidence, meaning it provides moderately strong observational evidence but not randomized controlled trial data.

Clinical Meaning and Caution

While the findings are interesting, they do not prove that CGRP inhibitors directly prevent glaucoma. Observational studies can show associations but cannot fully eliminate confounding factors such as:

• Differences in healthcare access
• Medication adherence
• Severity of migraine
• Undiagnosed eye disease at baseline

The authors also noted that detailed ophthalmologic measurements such as intraocular pressure trends and optic nerve imaging were not available in the dataset.

Why This Research Matters

Glaucoma is one of the leading causes of irreversible blindness worldwide, affecting over 100 million people globally. At the same time, migraine is a highly prevalent neurological disorder often requiring long-term preventive treatment.

If further research confirms these findings, CGRP inhibitors could have implications beyond migraine management, potentially contributing to broader neuro-ophthalmic protection strategies.

However, current evidence is not sufficient to recommend CGRP inhibitors specifically for glaucoma prevention.

Study Strengths and Limitations

Strengths

• Very large sample size
• Real-world multinational data
• Balanced comparison groups
• Multiple sensitivity analyses
• Consistent findings across different test models

Limitations

• Retrospective observational design
• Possible coding inaccuracies in medical records
• Lack of detailed eye examination data
• Incomplete control of all confounding variables
• Cannot confirm causality
• Treatment adherence not fully verifiable

Conclusion

This large-scale study published in Neurology by the American Academy of Neurology suggests that migraine patients using CGRP inhibitors may have a lower risk of developing glaucoma compared to those using traditional preventive medications.

The findings support a possible neurovascular link between migraine treatment pathways and ocular health. However, the evidence remains preliminary and should be interpreted cautiously until confirmed by prospective clinical trials.

Source

Chou, C.-C. et al. “Glaucoma Risk Associated With Calcitonin Gene–Related Peptide Inhibitor Use in Migraine: A Multinational Cohort Study.” Neurology, American Academy of Neurology, 2026.

Disclaimer

This article is for informational and educational purposes only. It is a paraphrased summary of a peer-reviewed research study and should not be considered medical advice. It does not diagnose, treat, or prevent any disease. Clinical decisions should always be made in consultation with qualified healthcare professionals.